What is the best clinical approach to adolescents with obesity and metabolic syndrome?

Abstract

Obesity in childhood and adolescence has increased worldwide and is being considered a public health issue [1]. Obesity is associated with a chronic proinflammatory state and many comorbidities, including, metabolic syndrome (MS) and nonalcoholic fatty liver diseases (NAFLD) [2,3]. Enlarged adipose tissue is a consequence of multifactorial conditions such as genetic and lifestyle factors including the increase in ultraprocessed and high caloric food consumption and a decrease in physical activity [4,5]. The expansion of adipose tissue promotes dysregulation of adipokine action, increasing the secretion of proinflammatory (i.e. leptin, resistin, plasminogen activator inhibitor-1, vistatin, angiotensin, tumor necrosis factor-alpha, interleukin 6) and concomitant reduction the anti-inflammatory adipokines like (adiponectin and interleukin 10). This pro-inflammatory state is considered key to the development of comorbidities related to obesity, such as MS [6]. The World Health Organization (WHO) defines MS as a pathological condition characterized by excessive abdominal obesity, insulin resistance, hypertension, and hyperlipidemia and its high prevalence around the world has today become a truly global challenge [1,7]. In fact, in adolescents with obesity, the prevalence of MS can reach up to 60%, which may disrupt its control in long-term weight loss interventions, with insulin resistance and visceral fatty being strong predictors [8]. Furthermore, the hyperleptinemic state is a common factor present in obesity in adolescents. The hyperleptinemic state is associated with disruption of neuroendocrine regulation of energy balance, atherosclerosis in early stage of the life, impairment on lung function and depression symptoms. In addition, it may impair the effects of interdisciplinary weight loss approach in the long term considering the pediatric population [9–12]. Inversely, the hypoadiponectinemia present in obesity can be reversed after leptin concentration was normalized with approximately 10% of weight loss. It is suggested that the balance between leptin and adiponectin may orchestrate the impact of weight loss therapy in adolescents with obesity and MS. In fact, previously, our research team showed that the adiponectin/leptin ratio is more effective as a biomarker of inflammation than these adipokines itself and should be considered in clinical practice [13–15]. Healthcare professionals must know what is behind the obesity phenotype in order to achieve reasonable goals in each patient and to define what strategy in each area should be used in order to improve not just body weight but body composition, inflammation profile, and metabolic disorders. Importantly, it has been shown that the impact of weight loss therapy in adolescents with MS occurs as a dependent manner considering of the presence of low or high number of altered parameters. Individuals with MS might need a longer time of multidisciplinary therapy to obtain similar results to those who do not have MS and to normalize the parameters that are altered such as blood pressure, dyslipidemia, insulin resistance, and so on [14]. Thus, this needs to be observed by the interdisciplinary team to find the better approach to treat this population. In the past 30 years an effort to understand the pathophysiology of obesity, MS and other co-morbidities in adolescents with obesity was developed by our research team and others. It was shown that this pediatric population present a constellation of altered parameters and conditions including insulin resistance, dyslipidemias, sleep apnea, asthma, lung function, NAFLD, depressive symptoms, eating disorders, together, contributing to a poor quality of life. On the other hand, the purposed multidisciplinary approach in the long term, including clinical, psychological, nutritional, and exercise approach was effective to reduce all the above-mentioned disorders, contributing to enhance the control of energy balance; inflammatory state, improving the quality of life and avoiding the development of yo-yo effects and many co-morbidities [2,3,9– 12,14,16,17]. The presence of many co-morbidities coexisting with obesity and MS related to pediatric population lead to our understanding that the best approach to treat these diseases is holistic, including medical professionals, psychologists, nutritionists, and exercise physiologists all working together (Figure 1).